SARS-CoV-2 Antiviral Peptide Discovery

The first case of novel coronavirus (SARS-CoV-2)–infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019. At the same time, there is an evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019 in Wuhan. Creative Biolabs is an excellent service provider and committed to providing a full range of SARS-CoV-2 antiviral peptide discovery services with high quality and low cost. Based on our advanced drug discovery platforms, we provide efficient and accurate peptide microarray analysis service as well as antiviral peptide discovery to support SARS-CoV-2 drug discovery.

Antiviral Peptides

During the battle against viruses, antiviral peptides (AVPs) has demonstrated the immense potential. AVPs are potential alternative methods and have been experimentally proven in blocking virus attachment or entry into host cells or inhibiting viral replication. It means that AVPs may interfere with the key steps of pathogenic human viruses. Furthermore, these inhibitory peptides can be used as starting point for the design of more active molecules targeting the generic steps involved in virus attachment, fusion and replication and so on. These peptides may be preferable due to their relatively low molecular weight, lesser toxicity, rapid elimination from the host, lesser side effects and also cost-effective synthesis nowadays. The mechanism of action of antiviral peptides is shown at Fig.1, as follows: 1, virion inhibition; 2, adsorption; 3, viral penetration; 4, endosomal escape; 5, viral uncoating; 6, viral genome replication; 7, release of mature virions.

Fig.1 Antiviral peptide inhibition sites on viral replication cycle. (Boas, 2019)

Antiviral Peptide Discovery Services Provided by Creative Biolabs

• Peptide microarray analysis service for SARS-CoV-2

Based on previous advanced experiences, Creative Biolabs provides peptide/protein microarrays service for clients to screen and detect the potent epitopes of a target peptide to support clients’ researches of SARS-CoV-2.

• Fusion peptide (EK1) for SARS-CoV-2 Treatment

EK1 (amino acids Glu (E) and Lys (K)), a modified OC43-HR2P peptide, has improved fusion inhibitory activity and increased solubility. There are many studies shown that EK1 peptide potently inhibits multiple CoV cell-cell fusions and blocks various pseudotyped and live CoV infections.

• ACE2-based peptide for SARS-CoV-2 Treatment

Angiotensin Converting Enzyme 2 (ACE2) is a novel and unique human homologue of the Angiotensin Converting Enzyme (ACE). ACE2 was identified as a main functional receptor for SARS-CoV. Therefore, ACE2-based peptide can be a candidate for the researches or/and treatment of CoV infection.

Features 

• Personalized platforms
• Experienced researchers
• High quality and time-saving manner
• Affordable prices

Based on our advanced techniques and years of experience, Creative Biolabs provides high-quality services for clients to analyze and design their antiviral peptides for SARS-CoV-2. During the projects, we will communicate with clients for their research plans in time and design the suitable outlines based on their requirements. If you are interested in more information about SARS-CoV-2 antiviral peptide discovery service, please don’t hesitate to contact us.

Reference

1. Boas, L. C. P. V.; et al. Antiviral peptides as promising therapeutic drugs. Cellular and Molecular Life Sciences. 2019, 1-18.

For Research Use Only. We do not provide direct services or products for patients.